pubmed-article:16887837 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16887837 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:16887837 | lifeskim:mentions | umls-concept:C0750952 | lld:lifeskim |
pubmed-article:16887837 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
pubmed-article:16887837 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
pubmed-article:16887837 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
pubmed-article:16887837 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:16887837 | pubmed:issue | 9 | lld:pubmed |
pubmed-article:16887837 | pubmed:dateCreated | 2006-10-9 | lld:pubmed |
pubmed-article:16887837 | pubmed:abstractText | Standard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer. | lld:pubmed |
pubmed-article:16887837 | pubmed:language | eng | lld:pubmed |
pubmed-article:16887837 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16887837 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16887837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16887837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16887837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16887837 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16887837 | pubmed:month | Sep | lld:pubmed |
pubmed-article:16887837 | pubmed:issn | 0368-2811 | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:IshiiHiroshiH | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:FunakoshiAkih... | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:MizunoNobumas... | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:UenoHidekiH | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:OkusakaTakuji... | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:IkedaMasafumi... | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:YamaoKenjiK | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:FuruseJunjiJ | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:NagaseMichita... | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:MorizaneChigu... | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:NakachiKoheiK | lld:pubmed |
pubmed-article:16887837 | pubmed:author | pubmed-author:HorikawaYukiY | lld:pubmed |
pubmed-article:16887837 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16887837 | pubmed:volume | 36 | lld:pubmed |
pubmed-article:16887837 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16887837 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16887837 | pubmed:pagination | 552-6 | lld:pubmed |
pubmed-article:16887837 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:meshHeading | pubmed-meshheading:16887837... | lld:pubmed |
pubmed-article:16887837 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:16887837 | pubmed:articleTitle | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. | lld:pubmed |
pubmed-article:16887837 | pubmed:affiliation | National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. jfuruse@east.ncc.go.jp | lld:pubmed |
pubmed-article:16887837 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16887837 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:16887837 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16887837 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16887837 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16887837 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16887837 | lld:pubmed |